Literature DB >> 6234393

Quality of life after cytotoxic chemotherapy: discussion paper.

T J Priestman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234393      PMCID: PMC1439814          DOI: 10.1177/014107688407700610

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  7 in total

1.  The current status of the treatment of childhood acute lymphoblastic leukemia.

Authors:  A M Mauer; J V Simone
Journal:  Cancer Treat Rev       Date:  1976-03       Impact factor: 12.111

2.  Treatment and survival on advanced breast cancer.

Authors:  T Priestman; M Baum; V Jones; J Forbes
Journal:  Br Med J       Date:  1978-12-16

3.  The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture.

Authors:  V T DeVita
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast.

Authors:  M Baum; T Priestman; R R West; E M Jones
Journal:  Eur J Cancer       Date:  1980       Impact factor: 9.162

5.  Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy.

Authors:  G P Maguire; A Tait; M Brooke; C Thomas; J M Howat; R A Sellwood; H Bush
Journal:  Br Med J       Date:  1980-11-01

6.  Evaluation of quality of life in patients receiving treatment for advanced breast cancer.

Authors:  T J Priestman; M Baum
Journal:  Lancet       Date:  1976-04-24       Impact factor: 79.321

7.  Adjuvant chemotherapy for breast cancer: side effects and quality of life.

Authors:  B V Palmer; G A Walsh; J A McKinna; W P Greening
Journal:  Br Med J       Date:  1980-12-13
  7 in total
  3 in total

Review 1.  Breast cancer management: quality-of-life and cost considerations.

Authors:  Davide Radice; Alberto Redaelli
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care.

Authors:  T Kurihara; Y Higashi; K Suemasu; T Tabei; S Ishiguro; Y Iino; Y Morishita; F Takeda
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

3.  Specialists should also be generalists: discussion paper.

Authors:  J W Todd
Journal:  J R Soc Med       Date:  1987-03       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.